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Adiponectin versus angiotensin 
II: Key pathological role of their 
misbalance
H Suzuki1,2 and S Eguchi1,2
Kurata et al. report that an angiotensin II type-1 receptor blocker 
(ARB) inhibits obesity-induced hypoadiponectinemia in rats through 
inhibition of reactive oxygen species generation. Taken together with 
the recently reported functional interplay between adiponectin and 
angiotensin II, this suggests that adiponectin probably mediates tissue-
protective effects of ARBs in obesity and metabolic syndrome.
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Although it has traditionally been con-
sidered a silent organ that passively stores 
excess energy, we now recognize adipose 
tissue as an important endocrine organ. 
Adipose tissue secretes a variety of bioac-
tive substances, which are called adipocy-
tokines, or adipokines. Of these adipokines, 
adiponectin has recently attracted much 
attention because of its antidiabetic eff ects. 
Two receptor forms have been cloned for 
adiponectin, AdipoR1, and AdipoR2. 
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These receptors contain seven-trans-
membrane domains. However, they are 
structurally and functionally distinct from 
traditional G protein-coupled receptors. 
Th us far, signal transduction of AdipoRs 
to stimulate insulin sensitization appears 
to involve activation of AMP-activated 
protein kinase (AMPK), p38 mitogen-
activated protein kinase, and peroxi-
some proliferator-activated receptor-α 
(PPARα).1 In addition to weight loss, an 
increase in adiponectin levels is observed 
after treatment with PPARγ-activating 
thiazolidinediones, which may be critical 
in their insulin sensitization. Although 
adiponectin is derived from adipose tissue, 
plasma concentration of adiponectin cor-
related negatively with a vast majority of 
risk factors, such as obesity, type 2 diabetes, 
glucocorticoids, testosterone, and hyper-
lipidemia. Moreover, recent studies suggest 
a strong link between cardiovascular dis-
eases and hypoadiponecinemia.1,2 In this 
regard, blockade of the renin–angiotensin 
system (RAS) appears to increase plasma 
adiponectin.3,4 Supporting this notion, 
angiotensin II (Ang II) infusion decreased 
plasma concentrations of adiponectin 
and adipose tissue levels of adiponectin 
mRNA.5 However, the molecular mecha-
nisms by which RAS inhibition stimulates 
adiponectin production remain unclear.
Kurata et al.6 (this issue) provide sig-
nificant insights into the molecular 
mechanism of RAS in adipokine regula-
tion.6 Th eir study demonstrates that ol-
mesartan, an Ang II type-1 (AT1) receptor 
blocker (ARB), inhibits obesity-induced 
hypoadiponectinemia. Olmesartan 
also ameliorates dysregulation of other 
adipokines, including tumor necrosis 
factor-α, plasminogen activator inhibi-
tor-1, serum amyloid A3, and monocyte 
chemotactic protein-1. Interestingly, 
the ARB also inhibits overexpression 
of reduced nicotinamide adenine dinu-
cleotide phosphate (NADPH) subunits 
and a transcriptional factor, PU.1 (which 
upregulates the transcription of NADPH 
oxidase subunits), in the obese tissue. In 
line with recent studies,7 reactive oxygen 
species (ROS) appear to reduce adiponec-
tin production in adipose tissue, which is 
inhibited by olmesartan. In addition to 
the inhibition of the AT1 receptor–ROS 
axis,6 there are two possible additional 
mechanisms by which ARB enhances 
adiponectin production (Figure 1). Some 
ARBs, including irbesartan and telmisar-
tan, have PPARγ-activating properties,8 
thereby stimulating adiponectin produc-
tion. Another mechanism is AT2 receptor 
activation in the absence of AT1 receptor 
activation. Such a phenomenon is sug-
gested by the fi nding that expression of 
PPARγ can be stimulated by AT2 recep-
tor activation in an AT1 receptor-defi cient 
cell model.8
In addition to its inhibitory eff ect on 
adiponectin production in adipocytes, 
the RAS also interacts with adiponectin 
in their target cells. Endothelial dysfunc-
tion, characterized as decreased nitric 
oxide (NO) bioavailability, is believed 
to be a key causal link between insulin 
resistance and cardiovascular diseases. In 
endothelial cells, adiponectin stimulates 
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endothelial NO synthase activity to pro-
duce NO through AMPK activation.9 By 
contrast, Ang II, through the AT1 receptor, 
stimulates ROS generation via activation 
of NADPH oxidase to induce endothe-
lial dysfunction (Figure 1). Ang II also 
induces endothelial insulin resistance to 
block endothelial NO synthase activation 
by insulin.10 Th erefore, the misbalance 
between adiponectin, Ang II, and insu-
lin sensitivity in endothelial cells could 
be a major determinant of the endothe-
lial dysfunction in metabolic syndrome. 
Adiponectin suppresses the proliferation 
of vascular smooth muscle cells, probably 
by inhibiting a mitogen-activated protein 
kinase, extracellular signal-regulated 
kinase (ERK), through AMPK.11 Ang 
II stimulates the ERK cascade through 
epidermal growth factor receptor trans-
activation,12 whereas AMPK inhibits the 
ERK activation in vascular smooth mus-
cle cells.13 Th us, adiponectin probably 
protects vascular remodeling induced 
by Ang II. Supporting this notion, in 
adiponectin-defi cient mice, neointimal 
thickening and increased accumulation 
of vascular smooth muscle cells were 
observed, whereas adenoviral transfer of 
adiponectin attenuated neointimal pro-
liferation.2 Similarly, overexpression of 
adiponectin in transgenic mice amelio-
rated atherosclerotic lesion formation.14
Taken together, these fi ndings suggest 
that supporting the adiponectin system 
by targeting the RAS might be very use-
ful for the treatment of cardiovascular 
and renal diseases associated with obes-
ity and metabolic syndrome. In addition 
to the thiazolidinediones and the RAS 
inhibitors, some dietary factors were 
reported to increase adiponectin levels. 
Further, AdipoR expression levels are 
reported to be increased by agonists of 
the nuclear receptors PPARα, PPARγ, 
and liver X receptor.1 Further investiga-
tion of the pathophysiological interaction 
among adiponectin, AdipoRs, and RAS, 
together with their interplay in signal 
transduction, is very fascinating and has 
the potential to lead to the discovery of 
novel treatment strategies for cardiovas-
cular and kidney diseases associated with 
obesity, metabolic syndrome, and type 2 
diabetes.
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Figure 1 | Pathophysiological signal-transduction interplay between adiponectin and 
angiotensin II. Peroxisome proliferator-activated receptor-γ (PPARγ) stimulates adiponectin 
transcription in adipocytes, whereas angiotensin II (Ang II) inhibits it through a reactive oxygen 
species (ROS)-dependent mechanism. Ang II type-1 (AT1) receptor blocker (ARB) stimulates 
adiponectin transcription by blocking Ang II binding to the AT1 receptor. Some ARBs directly 
stimulate PPARγ or may inhibit ROS as antioxidants (pleiotropic actions of ARBs). In the presence 
of an ARB, Ang II binds to the AT2 receptor. AT2 receptor activation stimulates PPARγ, leading 
to adiponectin production. In endothelial cells, adiponectin stimulates AMP-activated protein 
kinase (AMPK) to activate endothelial nitric oxide synthase (eNOS), resulting in nitric oxide (NO) 
production. This will antagonize Ang II-induced endothelial dysfunction. In vascular smooth 
muscle cells, adiponectin probably stimulates AMPK, which in turn inhibits extracellular signal-
regulated kinase (ERK) activated through epidermal growth factor receptor (EGFR) transactivation 
by Ang II. This will prevent vascular remodeling induced by Ang II. PPRE, PPAR-responsive element.
